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Abstract
Combinatorial phage library is a powerful research tool for high-throughput screening of protein interactions. Of all
available molecular display techniques, phage display has proven to be the most popular approach. Screening
phage-displayed random peptide libraries is an effective means of identifying peptides that can bind target
molecules and regulate their function. Phage-displayed peptide libraries can be used for (i) B-cell and T-cell epitope
mapping, (ii) selection of bioactive peptides bound to receptors or proteins, disease-specific antigen mimics,
peptides bound to non-protein targets, cell-specific peptides, or organ-specific peptides, and (iii) development of
peptide-mediated drug delivery systems and other applications. Targeting peptides identified using phage display
technology may be useful for basic research and translational medicine. In this review article, we summarize the
latest technological advancements in the application of phage-displayed peptide libraries to applied biomedical
sciences.
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Background
Phage display is a selection technique in which a peptide
or protein is fused with a bacteriophage coat protein and
displayed on the surface of a virion. This technology was
first described by George P. Smith in 1985, when he
demonstrated the display of peptides on filamentous
phage by fusing the peptide of interest to gene III of fila-
mentous phage [1]. Phage-displayed random peptide li-
braries enable functional access to the peptides and
provide a physical link between phenotype (the displayed
peptide) and genotype (the encoding DNA); these librar-
ies lend themselves to a screening process in which
binding clones are separated from nonbinding clones by
affinity purification.
Peptides binding to individual targets can be identified
by affinity selection (called biopanning). For biopanning,
a display library is incubated with an immobilized target,
followed by extensive washing to remove nonreacting
phages. Binders are usually eluted using acid or high salt
and are enriched by amplification in the appropriate host
cells. Three to five rounds of biopanning are usually per-
formed in order to obtain targets that bind with high af-
finity (Fig. 1). The primary structure of the peptide can
then be determined by sequencing the DNA of individ-
ual clones. Using this approach, it is easy to identify pep-
tides that bind specifically to target molecules.
Phage-displayed peptide library can be used in B-cell
and T-cell epitope mapping, selection of bioactive pep-
tides bound to receptors or proteins, selection of disease-
specific antigen mimics, selection of peptides bound to
non-protein targets, selection of cell-specific peptides,
selection of organ-specific peptides, and development of
peptide-mediated drug delivery systems and other applica-
tions. Targeting peptides identified using phage-displayed
peptide libraries have potential use in basic research and
translational medicine. In this review paper, we discuss in
detail each of the applications of the phage-displayed tech-
nology platform in the biomedical sciences.
B-cell and T-cell epitope mapping
Upon encountering antigen, host humoral immunity ac-
tivates and triggers production of antibodies directed
against foreign protein epitopes. Knowledge of these
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protein epitopes is pivotal in understanding the pathogen-
esis of pathogen infections and in developing diagnostic
reagents, therapeutic antibodies, and effective vaccines.
An epitope (known as an antigenic determinant) is recog-
nized by components of the immune system, including
antibodies, B cells, and T cells. The epitopes of antigens,
which are dependent on their structural properties, can be
either linear or conformational [2]. Linear epitopes have
some continuous amino acid sequences of antigens, which
correspond with their primary structure. In contrast, con-
formational epitopes contain discontinuous amino acid se-
quences of antigens, which are based on their protein
tertiary structure. There are several experimental methods
with which to identify B-cell epitopes, such as Pepscan [3],
co-crystallization [4], nuclear magnetic resonance (NMR)
[5], computational docking [6], and site-directed mutagen-
esis [7]. The phage display method provides an econom-
ical and rapid approach with which to map B-cell epitopes
[8–10]. Previous studies have used various phage-
displayed random peptide libraries to identify B-cell epi-
topes [11–15] or neutralizing epitopes [11, 14, 16] from
monoclonal antibodies (mAbs). In addition to mAbs,
polyclonal antibodies (e.g. special sera from patients or
immunized mice) can also be captured on solid disks or
magnetic beads, and then reacted with a comprehensive li-
brary of random peptides. Peptides have been selected by
biopanning with antibodies from complex sera of patients
with various diseases, including severe acute respiratory
syndrome (SARS) [17] and infection with human papillo-
mavirus (HPV) [18] and avian influenza viruses (AIV)
[19]. Based on information on B-cell epitopes from poly-
clonal antibodies, certain peptide-based antigens are use-
ful for serological diagnosis, and some are suitable for
development of vaccines [17, 20, 21]. The selected
disease-specific epitopes may prove to be invaluable for
the identification of the etiological agent [17] (Fig. 2).
Selection of disease-specific antigen mimics
The considerable potential of phage display peptide
libraries lies in their capacity to identify some peptide
molecules that mimic epitopes (named mimotopes).
Mimotopes have fewer similarities to primary amino
acids of antigens and always show discontinuous se-
quences, but they can elicit an identical or highly
Fig. 1 Application of biopanning with phage-displayed random peptide libraries. Random peptide libraries displayed on phages can be used for a number
of target candidates, including purified antibodies (B-cell epitopes), receptors (agonists or antagonists), enzymes (enzyme inhibitors), and carbohydrates
(antigen-mimetic peptides). After three to five rounds of biopanning, specific individual phage clones are selected and analyzed
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similar antibody response to that of the native epi-
tope. The development of diagnostic or preventive re-
agents requires screening phage-displayed peptide
libraries for disease-specific epitopes/mimotopes in
serum or cerebrospinal fluid samples obtained from
patients with viral infections [22, 23], rheumatoid
arthritis [24], multiple sclerosis [25], autoimmune
thrombocytopenic purpura [26, 27], and neurocysti-
cercosis [28]. Peptides have been selected by biopan-
ning serum samples from patients infected with HPV
[18], SARS [17], and AIV [19]. Mimotope-based de-
tection is suitable for broad spectrum antibodies
against avian H5N1 influenza virus [29], and has been
shown to improve serological detection of SARS [17]
and rheumatoid arthritis [30]. Another example is re-
cently identified cholera toxin-binding peptides. Chol-
era toxin, which is secreted by Vibrio cholerae, can
enter host cells by binding to GM1, a monosialogan-
glioside, and would result in acute diarrhea. Biopan-
ning with cholera toxin B (CTB) subunit to select
CTB-binding peptides that structurally mimic GM1
could serve as novel agents to block CTB binding on
epithelial cells and prevent the ensuing physiological
effects of cholera toxin [31].
Mimotopes can also be used to characterize un-
known initiating events and provide clues toward
disease pathogenesis. Biopanning with antibodies from
systemic sclerosis patients was used to screen an
immunopositive peptide that had a high degree of
similarity to autoantigens, including heterogenous ri-
bonucleoproteins (hnRNP), cytochrome c, fibrillarin,
and late protein UL94 of human cytomegalovirus
(CMV) [32]. Immunopositive peptide-based affinity
purified antibodies from sera of systemic sclerosis pa-
tients reacted with a surface component of endothe-
lial cells and induced apoptosis. A dengue anti-NS1
antibody B-cell epitope is cross-reactive to astrocyte
elevated gene-1 (AEG-1), a human protein on human
endothelial cells that may cause some dengue patients
to suffer from hemorrhagic fever (DHF) or dengue
shock syndrome (DSS) [33]. Recently, an antigen pep-
tide mimicking alpha-2–Heremans–Schmid glycopro-
tein, also known as fetuin-A, was identified from
serum antibodies of prostate cancer patients [34].
Using this antigen mimic peptide, the authors demon-
strated increased serum antibody reactivity to fetuin-
A during disease progression in the index patient,
and strong serum reactivity in a large cohort of meta-
static prostate cancer patients [34]. As mentioned
above, study of the disease-specific antigen mimics by
phage display helps us to understand the etiology of
diseases (Fig. 2).
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Fig. 2 Biopanning selection of phage-displayed peptide libraries using serum samples. The phage-displayed peptide library was precleared using normal
human sera and selected with serum antibodies (Abs) from patients with candidate diseases. After three rounds of biopanning, immunopositive phage
clones were screened by ELISA. Disease-specific epitopes were further identified and characterized by synthetic peptide binding and competitive-inhibition
assays. Phage-displayed disease-specific epitopes can be used to determine microbiological origins, study immunotyping, or provide information for the
development of diagnostic reagents and vaccines
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Selection of bioactive peptides bound to receptors
or proteins
For receptors
Membrane receptors are pivotal for cell-cell biochemical
and electrical signaling in essential physiological func-
tions. Therefore, the pharmaceutical industries tend to
focus on developing drugs targeting membrane receptors
[35, 36]. Novel receptor ligands discovered using phage-
displayed random peptide libraries [37–40] may be
either agonists or antagonists (Fig. 1). Two typical exam-
ples of agonist peptides selected by phage display are
peptides targeting erythropoietin receptor (EpoR) [37]
and thrombopoietin receptor (TpoR) [38]. After treat-
ment with Epo mimetic peptide, conformational changes
in the extracellular domain of EpoR trigger intracellular
signal transduction [37]. This discovery may form the
basis for the design of small molecule mimetics of Epo.
On the other hand, the selected small peptides targeting
TpoR can compete for the binding of the natural ligand,
thrombopoietin, and stimulate the proliferation of a
TPO-responsive cell line [38]. Antagonists of membrane
receptors from phage display have also been reported
[41–43]. For example, vascular endothelial growth factor
(VEGF) plays an important role in angiogenesis through
binding to the kinase domain receptor (KDR/FLK1 or
VEGFR2). Peptides as antagonists that block VEGF-
mediated angiogenesis have been obtained by phage dis-
play [43, 44]. Human CXC ligand 8 (hCXCL8) is a type of
chemoattractant that binds to hCXCR1 and hCXCR2,
which are involved in inflammation. Inhibition of hCXCL8
binding to hCXCR1 and hCXCR2 by antagonistic peptides
has been investigated, and used to develop new therapeu-
tics for treatment of inflammatory diseases [45].
Phage display is also used to isolate receptor-independent
peptide modulators, such as G protein-coupled receptors.
Some selected peptides from G proteins can interact with
the Gαi subunit, leading to an elevated sensitivity of guan-
ine nucleotides to bind to A1 adenosine receptors [46] and
to Gβγ subunit in order to enhance the dissociation of G
protein heterotrimers in vitro, and activate G protein
signaling in intact cells [47].
For enzyme inhibitors
The pathogenesis of some diseases occurs through the
expression of abnormal enzymes, which can serve as po-
tential targets for developing inhibitors as new drugs to
block the activities of these enzymes. Phage display has
been used to identify the peptide substrate inhibitors that
modulate enzyme activities [48, 49] (Fig. 1). Because fila-
mentous phages are resistant to a wide range of proteases,
they have been used to identify substrates and generate
protease inhibitors [50]. Bahudhanapati et al. identified se-
lective inhibitors of collagenase-1 (metalloproteinase 1,
MMP-1) by screening variants of tissue inhibitor of
metalloproteinases-2 (TIMP-2) using phage display.
TIMP-2 is a broad range inhibitor of matrix metallopro-
teinases (MMPs) [51]. In addition to protease inhibitors,
peptide-based inhibitors against various enzymes, such as
human HMG-CoA reductase [52], ubiquitin ligases [53],
and tyrosinase [54], have all been identified by phage-
displayed random peptide libraries.
Protein-protein interactions
In cells, protein-protein interactions regulate the mech-
anisms of several important normal physiological func-
tions. Phage display is a potent and versatile method
for studying protein-protein interaction [55–58]. It can
be applied to a wide range of protein interaction part-
ners and used in a number of applications, especially in
mapping intracellular interactions of the distinct pro-
tein domain. Good examples of protein interaction
partners include Src homology (SH) 3 domains, which
are highly conserved protein interaction modules com-
prised of 50 to 70 amino acids. SH3 domains are also
found in a variety of functionally unrelated proteins.
Kärkkäinen et al. generated a library in which all hu-
man SH3 domains are expressed on the surface of M13
bacteriophage, thereby enabling analysis of human SH3
domain binding to target proteins of interest, including
human immunodeficiency virus-1 Nef, p21-activated
kinase (PAK)2, and ADAM15 [59]. Voss et al. also
established similar libraries to define the SH3 domain
that reacts with the intracellular region of Fas ligand. In
addition to the known SH3 domains, the authors also
identified a number of additional SH3 domains that
may also be associated with FasL [60]. CDBP2 is a cel-
lular adapter protein that contains a GYF domain in its
C-terminal fragment. Kofler et al. identified a new con-
served motif, PPG (W/F/Y/M/L), in the GYF domain of
CDBP2, using phage display. Alignment of these con-
sensus motifs to protein databases, in combination with
yeast display or NMR methods, has allowed scientists
to rapidly identify novel interaction partners of GYF
domain [61, 62].
Selection of peptides bound to non-protein targets
Many different types of bacteria trigger protective immune
responses through cell surface non-protein antigens, such
as polysaccharides. Many tumor antigens are carbohydrates.
Epitopes mimicking low immunogenic polysaccharides or
carbohydrate antigens can be screened and identified by
phage-displayed random peptide libraries [63, 64] (Fig. 1).
These isolated peptide mimotopes coupled with carrier pro-
teins can be used as potential vaccine candidates to stimu-
late stronger antibody responses [65, 66].
The phage display technique has also allowed us to
identify novel peptides against RNA of interest by
screening random peptide libraries [67, 68]. Selective
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peptides targeting helix 31 of bacterial 16S RNA can
be used to inhibit cell-free translation [67]. Bose et al.
used phage display to find a selective peptide binding
to pre-miR-21, which blocks Dicer processing and de-
creases miR-21 expression [69].
A few studies have successfully employed peptide
phage display to select binders of small molecules,
such as fluorophores [70], microcystin-LR [71], and
paclitaxel (Taxol) [72]. Recently, Liu et al. performed
phage display to screen peptide ligands recognizing
an insecticide, imidacloprid, for environmental moni-
toring in water and soil [73]. The biopanning strategy
of phage display can be used to select specific
peptides against nanomaterials. These phage-displayed
nanomaterial binding peptides are broadly useful in
the field of nanotechnology [74]. Whaley et al.
showed the power of using combinatorial phage-
display libraries to select highly specific peptides that
bind to a range of crystalline semiconductor struc-
tures, such as GaAs, depending on the nanocrystal
orientation [75]. The application of specific peptides
has been extended to recognize other substrates of in-
organic nanocrystals, including ZnS, CdS, TiO2, and
SiO2, as well as magnetic materials such as Fe2O3
and Fe3O4 [76–79]. Peptides derived from phage-
displayed libraries can be specifically bound to a
conducting polymer for use as a biomaterial to func-
tionalize the surface of conductive polymers, thereby
enabling various electronic and biomedical applica-
tions [80]. Moreover, the Au-, Ag-, Ti-, Pt-, and Pd-
binding peptides were all acquired using the combinatorial
phage display peptide library [81–84]. Such metal and
semiconductor-targeting peptides have been genetically
engineered for use in nano- and biotechnology, particularly
in the molecular biomimetics field [84].
Selection of cell-specific peptides
Peptide phage display through whole-cell panning offers
a high-throughput approach for identifying peptides that
bind specifically to a single cell type. Johnston and co-
workers were the first to describe the use of peptide-
displayed phage to identify peptide binding to several
different cell types [85]. The most common screening
method is a process called “biopanning”, shown in Fig. 3,
in which the binding affinities of the targeted phage
clones are enriched. It can be performed in vitro against
various types of cells, including cultured cell lines, pri-
mary cells isolated from animal models or human pa-
tients, or processed cells (fixed cells, activated cells etc.).
Within the past ten years, several studies have focused
on the in vitro biopanning of phage displayed peptide li-
braries using various cancer cell types [86–90] to iden-
tify cell-specific ligands [91].
Depending on the applications of the ligand, selection
can be performed with adherent or fixed cells. The ex-
perimental approach can be modified to isolate phages,
which bind to the cell surface or peptides, thereby trig-
gering the cellular uptake of the peptides. Peptide-
displayed phage libraries are incubated with the cells for
a defined period of time. The cells are subsequently
washed to remove non-specific and weakly bound phage.
In order to reduce the cross-reactivity of the peptide or
the phage, blocking agents such as BSA are occasionally
used. Removing unbound phage is required to obtain
phage clones with strong binding to the desired target,
and remove non-specific binding from the background.
In general, the washing processes are relatively gentle;
however, more stringent washes may increase the affinity
of selected phage clones. In some cases, negative selec-
tion is performed to avoid the aforementioned problem.
In general negative selection is not essential.
Cells
Phage library
Bind
Cells
WashAmplify
Elute
Next round
Peptides
Fig. 3 The working principle for screening of cell-specific peptides from a phage display library. A phage display library was incubated with the
cells. Unbound phage was removed using washing buffer, and cells bound to phage were eluded and amplified with E. coli in broth. Enriched
phages were used in the next round of panning. After three to five rounds of selection panning, the positively selected phages were collected
and sequenced
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Phage bound to the target is recovered using several
elution strategies, including the use of acidic buffers,
Dithiothreitol, and high ionic strength, which tend to de-
crease the interaction between the peptide and the tar-
get. Most commonly, acidic buffer is sufficient for the
elution of target bound phage. However, in the case of
strong peptide-target interactions, these elution proce-
dures may only partially break peptide-target interac-
tions, thereby resulting in loss of the high-affinity phage
clones. To circumvent this problem, Strukelj and co-
workers used a modified method, in which ultrasound
was applied during acidic buffer elution to release
target-bound phage and enable the selection of high-
affinity phage clones [92]. In cases where ligands of a
particular target are known and available, competitive
elution is the preferred method of isolating the target
molecule. This method can specifically elute desired
target-bound phage clones while avoiding elution of
background-bound phage. Alternatively phage can also
be eluted competitively but nonspecifically by using the
free target molecule, such as an eluant, or by adding
bacterial host directly to the target-bound phage.
Using whole cells instead of purified proteins as target
for in vitro biopanning has several advantages. The cel-
lular receptors expressed on live cells can retain their
native states (correct protein folding, quaternary struc-
ture, expression level, and association with neighboring
proteins), and their biological functions and activities.
Biopanning with modified protocols can be used for the
isolation of peptides that mediate specific cellular func-
tions. For example, selection can be aimed at isolating
surface-bound or internalized peptides. Direction elution
of phage enables isolation of surface-bound phage. If
surface-bound phages are removed by low-pH washes or
through treatment with a protease, phage with internal-
izing characteristics can be isolated. In addition, the use
of whole cells for biopanning enables the identification
of cell surface molecules with unknown biological func-
tions. This can be used to characterize cell surface pro-
files and provide information on molecular changes
(such as expression level and protein localization) be-
tween normal and disease cells.
Although numerous cell-binding peptides have been
successfully isolated using in vitro panning against
cultured cells, several challenges still remain [91]. In par-
ticular, systematic experimental approaches for target
identification are lacking [93]. This is a key problem be-
cause accurate identification of peptide-targeted mole-
cules is important for basic and clinical research.
Conventional receptor identification focuses on mem-
brane protein extraction and affinity purification,
followed by mass spectrometric identification of the
purified protein. However, the problems associated with
this approach arise from the difficulty in maintaining the
native interaction between targeting peptide and isolated
whole membrane receptor [94]. Furthermore, the bind-
ing affinities of targeting peptides are, in general, too
low to enable purification by affinity-based methods. Wu
and co-workers aimed to overcome the problems
outlined above by using biotinylated peptides to directly
bind intact cells, and subsequent fixation of ligand-
receptor complexes by cross-linking with 3,3′-dithio-
bis[sulfosuccinimidyl propionate] (DTSSP). After affin-
ity trapping and LC-MS/MS analysis, the unknown
target protein on the plasma membrane of the cells
could be identified [89]. It is important to note that
advances in peptide identification and subsequent
receptor identification can lead to the discovery of
important cellular targets that were previously
unknown. This not only improves our understanding
of the molecules expressed in the pathological state,
but may also provide useful information on molecules
that are not expressed under normal physiological
conditions.
Selection of organ-specific peptides
Organ-specific peptides can be isolated from phage dis-
play peptide libraries by performing the selection in a
living animal. In vivo phage display technology was first
described by Ruoslahti and co-workers in 1996 [95].
They aimed to discover brain vasculature targeting pep-
tides using phage-displayed peptide libraries. Typically, a
random peptide phage library is introduced by intraven-
ous injection into the circulation of animal. After a brief
circulation time, the animals are sacrificed, and the un-
bound phage clones are washed off through perfusion of
the left ventricle with saline. Based on the half-life of the
phage in previous studies, the circulation time of a
peptide-displayed phage is generally estimated to be in
the 5 to 15 min time range [86, 96, 97]. There is evi-
dence that the displayed exogenous peptide or protein
can exhibit circulation half-lives as short as 1.5 min to
as long as 4.5 h [98, 99]. Molenaar and co-workers
reported that degradation of phage occurs as rapidly as
30 min after injection [98]. A circulation time of over
30 min may be caused by lysosomal degradation of
phage after uptake by the target tissue.
After removing the unbound phage in circulation, the
desired organs are collected and homogenized. The
organ-associated phage is recovered from the homoge-
nized tissue. A fraction of the organ lysates are used to
infect bacteria for phage amplification and for subse-
quent rounds of selection in another animal. Another
fraction is used for phage titering to measure the
amount of recovered phage. After 3–5 rounds of in vivo
biopanning, the phage titer recovered from the target
tissue should increase [88, 97, 100]. Several peptide mo-
tifs are typically identified for a given organ (Fig. 4).
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After biopanning, the specificity of the isolated peptide
needs to be further confirmed. In general, wild type
phage without insert or phage with scrambled peptide is
used as a negative control. The ability of the isolated
peptide to home to the target organ can be confirmed
either by comparative analysis using a scrambled pep-
tide, or by competitive studies using a combination of
synthetic peptide and selected phage clone with identical
peptide sequence. Other approaches, such as immuno-
staining of homing phage, or fluorescent or radioactive
labeling of either phage or synthetic peptide, can be used
to directly determine the organ tissue distribution.
This approach has been applied to a number of different
organs, including brain, kidney, lungs, liver, uterus, muscle,
pancreas, thymus, and mammary gland [101]. Various
types of tumor and malignant tissue vasculature have been
targeted using phage-displayed random peptide libraries
[97, 101–105]. In addition to tumor blood vessels, many
tumors induce the growth of new lymphatic vessels and
change characteristics during tumor development. Several
researchers have used the in vivo phage display technology
to map tumor-specific differences in the lymphatic vascula-
ture, and have identified peptides that specifically home to
tumor lymphatics [106].
Using in vivo phage display technology to identify spe-
cific homing peptides is not without pitfalls. Peptides
isolated from animal models using this method may not
translate to human because of differences in the vascula-
ture and peptide binding between species. Such limita-
tions can be overcome by performing biopanning in
humans. The phage library can be injected into terminal
human patients and retrieved from human tissues to
identify organ specific peptides [107]. Another study re-
ported the use of phage-display libraries in cancer
patients to identify tumor-targeting ligands [108]. In vivo
phage display has been shown to be an effective and
powerful technique for the isolation of peptides that spe-
cifically bind to an organ with high affinity and specifi-
city. However, optimization of these peptides is needed
to enhance the clinical applicability of in vivo phage dis-
play research.
Development of peptide-mediated drug delivery
systems
The delivery of anti-cancer drugs to solid tumors is lim-
ited by physical transport barriers within tumors, and
such restrictions directly contribute to decreased thera-
peutic index and the emergence of drug resistance. Drug
delivery systems designed to precise spatiotemporal
control have demonstrated potential to enhance drug
delivery in animal models. Many nanoparticle delivery
systems for anticancer drugs have entered the clinic,
where they have been shown to exert anticancer effects
by improving the pharmacokinetic and pharmacody-
namic properties of their associated drugs [109]. Lipo-
somes are the most advanced form of particulate drug
carriers. Liposomal systems, like RES-avoiding and long-
circulating systems, can confer stable formulation,
improved pharmacokinetics, and “passive” targeting of
tumor tissue. The newest generation of drug carriers uti-
lizes multicapable nanotechnology-oriented strategies
aimed at greater specificity and efficiency. They feature
direct molecular targeting of cancer cells via ligand-
mediated interactions. Molecular targeted drug delivery
can be achieved using targeting liposomes created by
linking liposomal drugs to specific ligands. The develop-
ment of targeting liposomes has been made possible by
advances in liposomal systems. These two technologies
Phage 
library
i.v. injection
Phage circulationElution and
amplification
Recovery
Next round
Brain
Heart
Lung
Tumor
Phage titteringPhage circulation
Sacrifice
phage
i.v. injection
PBS perfusion
Dissection
Fig. 4 Use of phage display libraries to identify peptides that bind to a specific organ. a The in vivo process is based on panning the library of
peptides against the target organs. The phage peptide library is injected into the mouse’s tail vein to allow it to circulate throughout the body.
After a few minutes in circulation, phage molecules that bind to organs and tissues of interest are isolated. The isolated phage molecules are
amplified and subjected to further rounds of selection to enrich organ-specific phage. Finally, DNA from the phage is sequenced to identify the
encoded peptide, and the peptide can be used for the development of organ-specific therapeutics and diagnostics. b The specificity of selected
phage clones can be further confirmed using the phage homing assay. Mice are injected with the selected phage clones through the tail vein.
Phage clones are allowed to circulate, and the nonspecific binders are washed out. The organs are subsequently recovered, and the titers of phage in
various organs are determined
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can in principle be fully integrated, thus combining the
specificity of ligands with the drug delivery capabilities
of liposomes (Fig. 5).
Peptide-mediated liposomes include three main
components: an anticancer drug, a liposome carrier,
and targeting ligands (Fig. 5). Remote loading methods,
such as the ammonium sulfate method [110] and the pH
gradient method [111], can encapsulate weak bases, such
as doxorubicin or vinorelbine, into the liposomes with
more than 95 % efficiency [89]. Schedule-dependent
drugs, such as vinca alkaloids and topotecan, are reason-
able candidates for liposomal delivery because of their
effectiveness at enhancing the exposure time of cancer
cells to therapeutic drug levels. The use of peptide-
mediated liposomes also avoids exposing normal tissue to
cytotoxic drugs, and prevents adverse side effects.
High tumor interstitial fluid pressure (IFP) is a barrier
for efficient drug delivery [112, 113]. Increased IFP
contributes to decreased transcapillary transport in
tumors, which reduces uptake of drugs. This ap-
proach sidesteps the problem of high tumor IFP [89,
113, 114] and improves treatment effectiveness,
thereby reducing incomplete tumor response, rapid
disease relapse, and development of drug resistance
due to suboptimal doses, which are often seen when
using conventional chemotherapies.
The use of peptides as targeting ligands offers sev-
eral advantages, including ease of synthesis, structural
simplicity, low cost, low immunogenicity, small size,
ready diffusion, and simple targeted formulation as-
sembly, as compared to larger biomolecules, such as
antibodies. Previous studies showed that using larger
biomolecules as targeting ligands may increase the
clearance of antibody-modified nanoparticles from the
blood [115–117]. This may be due to non-specific
binding and uptake of nanoparticles by the RES [116].
Earlier studies with other targeted delivery systems
have suggested that targeting moieties increase drug
accumulation in tumor tissues [118, 119]. However,
targeted nanoparticles have not always caused a sig-
nificant increase in overall tumor accumulation as
compared to the non-targeted drugs. The use of
macromolecule-targeting ligands, such as antibodies
[120] or transferrin [121], has a negligible impact on
tumor accumulation and biodistribution. The differen-
tial effects of nanoparticles modified with macromole-
cules and those modified with small molecules may
be due to differences in molecular size, affinity, and
penetrability of the targeting ligand [122]. It is
possible that targeting moieties with high affinity
would be subject to greater internalization and
degradation by perivascular tumor cells, thereby
Free Drug Targeted liposomal drugLiposomal Drug
Combination of
targeted liposomal drugs
Tumor PEG
Doxorubicin
crystals
Vinorelbine
crystals
Targeting
ligandLiposome
Side effect Therapeutic efficacy
Therapeutic
index
Fig. 5 Combination chemotherapy with ligand-targeted delivery of doxorubicin and vinorelbine. Conventional cancer chemotherapy results in the non-
specific distribution of toxic therapeutic agents in the human body, which induces adverse side effects. To minimize such side effects, attempts have been
made to encapsulate the drug in nanoparticles (e.g., liposomes with encapsulated doxorubicin). Although liposomal doxorubicin has fewer adverse effects
than those of free drugs, its therapeutic efficacy is insufficient. The specificity of nanoparticles can be further enhanced through modification with targeting
ligand. Some cancer cell types develop drug resistance over the course of drug treatment. The use of targeted nanoparticles to deliver
multiple chemotherapeutics (with different mechanisms of action) specifically to cancer cells may simultaneously enhance therapeutic
efficacy and reduce undesirable side effects
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limiting their penetration of tumors and reducing
their tumor retention [123, 124].
Colorectal cancer is one of the most commonly diag-
nosed cancers and a leading cause of cancer death
worldwide. Traditional chemotherapy only has limited
therapeutic efficacy due to non-specific delivery to
tumor and non-tumor cells, and the development of
drug resistance by cancer cells. Therefore, there is an ur-
gent need to develop more tumor-specific targeted drug
delivery systems that can more accurately and effectively
deliver the anti-cancer chemotherapeutic drugs to the
tumor sites. In a recent study, Wu et al. used phage dis-
play technology to identify three peptides that could
bind to colorectal cancer cells with high specificity and
binding affinity [89]. The authors successfully developed
a targeted drug by conjugating these peptides to lipo-
somes. This novel targeted liposomal drug combination
specifically delivers chemotherapeutics to tumors, result-
ing in a much higher dose of drugs being accumulated
at the tumor site. This significantly increased the tumor
inhibition abilities of these two types of chemotherapeu-
tic drugs, and effectively eliminated cancer without indu-
cing any side effects for 150 days, with no trace of
recurrence [89]. Thus, this study demonstrated that
drugs can be accurately delivered to tumor sites by com-
bining the liposomal drugs with peptides generated
using phage display technology, resulting in a next-
generation targeted anti-cancer drug delivery system.
Advances in nanotechnology have facilitated a multi-
disciplinary approach toward the development of an
ideal “smart nanodrug delivery system,” which can be
decorated with a targeting ligand for diagnostic or im-
aging uses, in addition to therapeutic agents of interest
(Fig. 5). The availability of such “smart nanodrug deliv-
ery systems” in the near future will allow us to detect,
diagnose, target, modulate delivery of, and track the pro-
gression of therapy both remotely and noninvasively.
Discussion
Combinatorial phage-displayed random peptide libraries
are very valuable tools for studying the interaction be-
tween peptides and other substances (or materials). In
the past, scientists have been focused on identifying B/T
cell epitopes [11–19], disease-specific antigen mimics
[22–34], receptor agonists/antagonists [35–45], enzyme
inhibitors [48–54] and protein partners [55–62]. In re-
cent years, there is an increasing number of researchers
who apply this technique to new areas of studies, such
as chemistry [70–72] and materials [74–84] science. Al-
though phage display is a powerful technique, it still has
some disadvantages. Choosing suitable phage display li-
braries (i. e. the number of phage-displayed amino acid
residues), using applicable selection condition, ensuring
the stability and the quality of phage display libraries
and following the appropriate screening protocols are all
important factors that could impact the quality and de-
sirability of the ligand peptides generated. If these key
parameters can be established, functional target peptides
are more likely to be obtained. Furthermore, combin-
ation of peptide information from phage display with
bioinformatics resources may improve the quality of
peptides. Tian et al. [125] and Sandman et al. [126] in-
corporated genetically-encoded non-natural amino acids
into phage-displayed libraries and paved the way for
wider chemical diversities. Woiwode et al. [127] also
combined a new phage-displayed hybrid system with
synthetic chemistry through one-compound-one-clone
principle (each compound was encoded by a unique nu-
cleotide sequence inserted in a non-coding region of the
phage genome). These new techniques help to further
advance the possible applications and potentials of phage
display going forward.
Cancer cells, different from normal cells, are often
found to overexpress certain antigens. Molecules which
can recognize these tumor antigens with high specificity
are suitable candidates as potential agents for guiding
cancer chemotherapy to target tumor sites. The thera-
peutic monoclonal antibody, antibody-drug conjugates
(ADCs), peptide-drug conjugates (PDCs) and peptide-
mediated drug delivery systems have a major impact on
the field of cancer therapy. Therapeutic monoclonal
antibody based therapies have achieved remarkable clin-
ical success and become one of the most important
strategies for treating patients with hematological malig-
nancies and solid tumors. The direct action of antibodies
by receptor blockade or agonist activity may have limited
therapeutic activity. Antibody-dependent cellular cyto-
toxicity (ADCC) and complement-dependent cytotox-
icity (CDC) have been demonstrated to have a major
role in antibody efficacy [128, 129]. Unfortunately, anti-
body treatment of patients with malignant tumors may
not achieve therapeutic effect due to immune suppres-
sion, immune escape, complement inhibition etc. ADCs
offer the possibility to overcome this issue by enhancing
cytotoxicity to cancer cells, thereby reducing undesired
side effects. Although ADCs have already been approved
as anticancer therapy, there remain several limitations to
this type of therapeutics, such as tumor penetration,
high manufacturing costs, and challenging conjugation
chemistry [130].
PDCs have similar promise as ADCs but they differ in
their pharmacological outcomes. Compared to ADCs,
PDCs have additional advantages of having smaller mo-
lecular mass, higher tissue penetration, enhanced flexibil-
ity and well-defined conjugation chemistry, and faster and
easier synthesis process when prepared in a homogenous
form [130]. Several peptides included RGD motif peptides
[131–136], cell penetrating peptides [137–141], and tumor
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cell specific peptides [142–145] are used for synthesizing
PDCs for cancer therapy. After more than decades of re-
search, lots of PDCs have been discovered, and some have
been clinically evaluated, although none has yet received
regulatory approval. One of the PDCs that has been clinic-
ally evaluated and carry most promising is GRN1005.
GRN1005 is a LRP-1-targeted peptide-drug conjugate that
covalently links paclitaxel to the proprietary 19 amino acid
peptide angiopep-2, in a 3:1 ratio. The results from the
phase I trial of GRN1005 showed the drug candidate to
have acceptable safety profile. GRN1005 is currently
undergoing Phase II trials to demonstrate the efficacy,
safety, and tolerability of GRN1005 in patients with brain
metastases from non-small cell lung cancer
(NCT01497665). In addition, GRN1005 in combination
with Trastuzumab (Herceptin®) has advanced to Phase II
studies as a therapeutic agent for HER2 positive metastatic
breast cancer (NCT01480583) [146]. However, one major
drawback of PDCs that limits their clinical uses is their
stability. PDCs are highly proteolytic unstable, which re-
sults in their short half-life in circulation and poor
pharmacokinetics. In addition, the relative small molecular
weight of PDCs would be rapidly eliminated through renal
excretory system.
Neither ADCs nor PDCs allows for high drug payloads
on the conjugates molecule. The major challenges facing
most ADCs and PDCs are their relatively low capacity
for drugs. Hence, more effective payload strategies using
different carriers are urgently needed. In addition to
ADCs and PDCs, nanoparticles modified with targeting
ligand are more effective payload strategies. Nanoparti-
cles as potential vehicle for encapsulating chemothera-
peutics can achieve higher drug-loading efficiency.
Nanoparticles have been shown to increase the drug-
loading capacity by approximately a thousand-fold com-
pared to ADCs and PDCs [89]. Much enhanced drug
loading capacity and higher tumor cell specificity render
nanoparticles as potentially more promising targeted
drugs as a result of their higher efficacy and lower tox-
icity [89]. ADCs, PDCs and peptide-mediated drug deliv-
ery systems have shown considerable promise in
improving the delivery of drug to tumor and limiting
off-target toxicities simultaneously. These targeting ther-
apeutics represent promising new frontier in cancer
treatment.
Despite having the advantages of increased therapeutic
efficacy, many challenges still remain for nanoparticles,
including potential for off-target effects, ligand stability,
immune responses triggering and drugs delivery effi-
ciency in the cytoplasm of target cells. In particular, the
rapid clearance of these nanodrugs by the cells of the re-
ticuloendothelial system (RES)/mononuclear phagocyte
system (MPS), especially liver and spleen, can lead to in-
creased toxicity to the off-target organs and reduced
therapeutic efficacy. However, a recent publication sug-
gested that such off-target effects can be reduced by
Intralipid 20 % (a FDA-approved fat emulsion used as
parenteral nutrition source), which could decrease the
toxicities in liver and spleen and increase the bioavail-
ability of dichloro (1, 2-diaminocyclohexane) platinum
(II)-loaded and hyaluronic acid polymer-coated nanopar-
ticle (DACHPt/HANP) by possibly inhibiting peritoneal
clearance and impairing the phagocytic activity of Kupffer
cells [147]. Whether such reduced off target effects can
also be observed in liposomal based drug delivery system
is worthwhile further investigating.
Drug delivery using antibodies or ligands that bind to
specific receptor molecules on tumor target cells allow in-
creased drug accumulation at the target tumor site, how-
ever, the actual percentage of drug accumulated at the
tumor site was often only a few percent of the total dose
administered. Identification of effective ligand-receptor
interaction may help to improve the effectiveness of active
targeting. In the field of targeted drug delivery, scientists
still have a long way to go, but this may change within the
next couple of years. Over time, the number of targeted
drug-delivery nanoparticles approved by the FDA is
expected to increase.
Conclusions
Although cancer drugs continue to be discovered, most
of these drugs have only limited efficacy against cancer,
with less than ideal ability to prolong the lives of cancer
patients. Small molecule drugs have the advantage of
having higher tissue penetration abilities, but they are
non-specific to tumors and have a relatively short half-
life. Protein drugs are highly tumor-specific; however,
they have lower tumor penetration abilities due to their
larger molecular sizes. Peptide-mediated drug delivery
systems combine the potent small molecule drugs with
high specificity of peptides, thus leveraging the benefits
of the two therapeutic regimens while reducing their dis-
advantages. An ideal drug delivery system should achieve
a high level of clinical efficacy and minimize the adverse
effects. The development of targeting liposomes can im-
prove drug delivery to the target tissue and reduce drug
distribution to nontarget tissues, resulting in increased
therapeutic activity with minimal side effects. Peptide-
mediated liposomes that target tumor cells and vascula-
ture represent a new generation of chemotherapeutic de-
livery systems. They offer superior pharmacokinetics,
controlled biodistribution, greater efficacy, and enhanced
safety profiles, and simultaneously improve eradication
of disease and reduce common side effects. This has
been a long sought-after goal in the development of che-
motherapeutic drugs. The modular organization of tar-
geting liposome technology makes it possible to
combine peptides with a series of liposomal drugs to
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yield next-generation targeted agents, such as peptide-
mediated targeting liposomes. However, to date, no
peptide-drug conjugates or peptide-modified nanoparti-
cles have successfully reached the market. However, cer-
tain hurdles must be overcome before peptides can be
widely used as targeting moieties, including development
of the appropriate ligand for the targeted receptor, un-
derstanding the mechanisms of ligand-receptor uptake,
disposition, trafficking, and recycling, and compliance
with Chemistry, Manufacturing, and Control (CMC)
requirements.
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